Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
Open Access
Abstract
Several intravenous iron complexes are available for the treatment of iron deficiency anemia (IDA). Iron dextran (DEX) is associated with an elevated risk of potentially serious anaphylactic reactions, whereas others must be administered in several small infusions to avoid labile iron reactions. Ferric carboxymaltose (FCM) is a nondextran intravenous iron which can be administered in high single doses. A randomized, open label, and multicenter comparison of FCM to DEX in adults with IDA and baseline hemoglobin of ≤11.0 g/dL was conducted. A total of 160 patients were in the safety population (FCM; DEX). Adverse events, including immune system disorders (0% in FCM versus 10.3% in DEX,) and skin disorders (7.3% in FCM versus 24.4% in DEX,), were less frequently observed in the FCM group. A greater portion of patients in the FCM group experienced a transient, asymptomatic decrease in phosphate compared to patients in the DEX group (8.5% in FCM versus 0% in DEX,). In the FCM arm, the change in hemoglobin from baseline to the highest observed level was 2.8 g/dL, whereas the DEX arm displayed a change of 2.4 g/dL (). Treatment of IDA with FCM resulted in fewer hypersensitivity-related reactions than DEX.
Keywords
Funding Information
- Luitpold Pharmaceuticals, Inc.
This publication has 30 references indexed in Scilit:
- Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center studyNephrology Dialysis Transplantation, 2012
- Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled TrialsAnemia, 2012
- Clinical Use of Intravenous Iron: Administration, Efficacy, and SafetyHematology-American Society Hematology Education Program, 2010
- Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemiaArzneimittelforschung, 2010
- Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytolClinical Kidney Journal, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Ferric CarboxymaltoseDrugs, 2009
- Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trialAmerican Journal of Obstetrics and Gynecology, 2008
- Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemiaInternational Journal of Gynecology & Obstetrics, 2008
- Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patientsNephrology Dialysis Transplantation, 2005